Rapid diagnostics healthcare technology company Lumos Diagnostics will be a hot IPO to watch. It has great product, fantastic leadership, wider market reach and accelerating its expansion. Below are key summary:
- Founded in 2015
- Core Product is a world-first finger prick blood test called FebriDx, which can indicate if a person has a bacterial or viral infection within 10 minutes i
- Other main offering is point-of-care diagnostics tests and proprietary digital reader platforms
- Revenue : In the six months to December 31, Lumos’ revenue tripled to $11.5 million, compared with the previous corresponding period
- Market reach: Australia, UK, Germany, Canada , US
- Pre-ipo: In October, the company closed a $25 million funding round
- Recent deal: a deal with Italian multinational diagnostics biotech DiaSorin to manufacture and launch its immunoassay point-of-care platform.
- Key backing: Perennial Value Management and Ellerston Capital
- Broker and listing date to be confirmed
- Forums
- IPOs
- Lumos Diagnostics
Rapid diagnostics healthcare technology company Lumos...
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
RDN
RAIDEN RESOURCES LIMITED
Dusko Ljubojevic, MD
Dusko Ljubojevic
MD
SPONSORED BY The Market Online